November 26, 2015


Biovotec will present at 9:15 on the 15th of December at the DNB's Yearly Health Care Conference, held at DNB's head offcie, Dronning Eufemieas gate 30 in Oslo.


DNB selects every year a number of promising and upcoming medical and medical device companies to mainly Sc...

In the granted EU SME Phase 2 project, Biovotec will work with Finesse Medical in Ireland to produce the final wound healing medical device which will be used in the clinical trials to be conducted in 2016. Finesse Medical is a specialty wound healing manufacturer whi...

38 SMEs from 13 countries have been selected in the latest round of Horizon2020 SME Instrument Phase 2. Taking into account that over 8000 companies have applied for the qualifying SME Phase 1 grant, the overall success rate was very small. In Norway only 2 projects in...


Biovotec is developing advanced wound care products combining functionality with an unprecedented competitive price, offering an unrivaled advantage for both patients and clinicians. Biovotec is using the unique raw material obtained from egg shell membranes. The uniq...

CEO Ralf Schmidt raised another 15 million NOK in new capital and now he is asked to present Biovotec to the British health authorities.



Please reload

Media Contact:     +47 95 94 99 78

Recent Posts
Please reload

Please reload

Engebrets vei 3, 0275 Oslo, Norway                                                   © Biovotec AS                                                                       info@biovotec